Table 3 Clinical efficacy of ketamine compared with placebo for both cohorts combined
From: A randomized, placebo-controlled, cross-over trial of ketamine in Rett syndrome
Both Cohorts (n = 21) | ||||
|---|---|---|---|---|
Measure | Placebo LSM (SE) | Ketamine LSM (SE) | Difference (95% CI) | Treatment (p-value) |
MBA | 44.56 (2.63) | 45.57 (2.63) | 1.01 (−0.73, 2.75) | 0.2373 |
CGI-I | 3.81 (0.09) | 3.79 (0.09) | −0.01 (−0.22, 0.19) | 0.8895 |
ClinDom | 33.25 (0.96) | 33.67 (0.96) | 0.42 (−0.63, 1.46) | 0.4149 |
RSBQ | 38.04 (2.77) | 38.97 (2.77) | 0.93 (−2.13, 3.99) | 0.5315 |
CSHQ | 106.39 (5.90) | 99.19 (5.90) | −7.19 (−16.48, 2.09) | 0.1213 |
ParDom | 33.58 (1.93) | 34.29 (1.93) | 0.71 (−0.97, 2.39) | 0.3877 |
RTT CIA | 34.50 (3.44) | 33.54 (3.44) | −0.96 (−3.73, 1.81) | 0.4779 |